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Till F. Schberle,[a] and Gabriele M. Kçnig*[a]
Introduction
Myxobacteria belong to the d-subdivision of Proteobacteria
and are an important source of new biologically active metab-
olites, including antibacterial, antifungal, antiplasmodial, and
antitumor agents.[1] The most prominent examples are the
epothilones, of which a semisynthetic derivative—ixabepilone
(Ixempra)—was approved in 2007 for the treatment of breast
cancer.[2]
The majority of the myxobacterial compounds isolated so
far are polyketides (PKs), nonribosomal peptides (NRPs), or PK/
NRP hybrid molecules. These natural products are synthesized
by large multifunctional enzymes: that is, polyketide synthases
(PKSs) and nonribosomal peptide synthetases (NRPSs).[3, 4] Out
of over 30 identified myxobacterial biosynthetic gene clusters,
only eight encode for pure PKSs and two for NRPSs, whereas
the vast majority encode for PKS/NRPS hybrids.
Most myxobacterial PKSs and NRPSs have a modular organi-
zation, in which each module catalyzes the incorporation of
one building block into the nascent molecule. Each module is
further subdivided into domains: enzymatic units that are re-
sponsible for loading, condensation, and further modification
of the extender unit in question. This one-to-one correspond-
ence between domains and biosynthetic transformations is
known as “colinearity”, and allows the deduction of extension
cycles from the number of modules, as well as certain structur-
al features such as the oxidation state of a building block,
directly from the genetic information.[3,5, 6] Conversely, a “retro-
biosynthetic analysis” of a compound’s structure enables the
prediction of the domains involved in its biosynthesis.
Three representatives of a new class of compounds—phe-
nylnannolones A–C (Scheme 1)—were previously isolated by
our group from the halotolerant myxobacterium Nannocystis
pusilla B150.[7] For phenylnannolone A, the main metabolite of
this series, inhibitory activity towards P-glycoprotein (P-gp)
could be shown. P-gp is an ABC-transporter responsible for the
efflux of drugs from cells, such as anticancer agents from
tumor cells, which results in treatment failure. We were able to
show that co-treatment of drug-resistant cancer cells with phe-
The myxobacterial strain Nannocystis pusilla B150 synthesizes
the structurally new polyketides phenylnannolone A–C. Apart
from some common volatiles and siderophores, these are the
first natural products from the genus Nannocystis. Phenylnan-
nolone A shows inhibitory activity towards the ABCB1 gene
product P-glycoprotein and reverses daunorubicin resistance in
cancer cells. To decipher the biochemical reactions leading to
the formation of phenylnannolone A, the putative biosynthetic
genes were identified (phn1, phn2). Phn2 is a polyketide syn-
thase (PKS) with an NRPS-like loading module, and its domain
order is consistent with the phenylnannolone A structure. The
functionality and substrate selectivity of the loading module
were determined by means of a g-18O4-ATP pyrophosphate
exchange and a phosphopantetheine ejection assay. A specific
activation of cinnamic acid by the AMP-ligase was detected.
Phn1 is a putative butyryl-CoA carboxylase (BCC), providing
ethylmalonyl-CoA for the formation of the ethyl-substituted
part of phenylnannolone A. Phn1 is the first BCC found in bio-
synthetic genes for an ethyl-substituted natural compound.
Biosynthesis of phenylnannolone A, putatively encoded by
phn1 and phn2, thus utilizes the first biosynthetic machinery
in which both a BCC and a PKS are involved.
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nylnannolone A and daunorubicin resulted in a tenfold de-
crease in resistance to the anticancer drug.[7] The effect of the
nontoxic phenylnannolone A was thus comparable with those
of P-gp inhibitors of the third generation, such as tariquidar.[8, 9]
For a deeper understanding of the biochemical reactions
involved in the formation of phenylnannolone A, our current
investigation addressed the elucidation of the biosynthetic
genes for phenylnannolone A. Here we present the first bio-
synthetic genes from myxobacteria of the genus Nannocystis
(Figure 1).
Results and Discussion
Identification of the biosynthetic genes
Investigations into the biosynthesis of phenylnannolone A with
labeled precursors revealed acetate, butyrate, and a phenylala-
nine-derived starter unit as building blocks (Scheme 1). Unex-
pectedly, acetate labeling experiments established the incorpo-
ration of the C-2 carbon atom (i.e. , the methyl group) of an
acetate unit in position 9.[7] From the labeling pattern it can be
deduced that the lactone ring and parts of the polyene chain,
including the ethyl side chain, originate from a PKS, which,
due to the phenylalanine incorporation, must have an NRPS-
like loading module.
Genome sequencing provided 3804 contigs with an average
contig size of only 3 kb and a 16.6-fold coverage of the
genome. All contigs were screened by using BLAST and CLU-
SEAN software for PKS genes with DNA information for keto-
synthase (KS), acyltransferase (AT), dehydratase (DH), keto-
reductase (KR), and thioesterase (TE) domains.[10,11] Because of
the small sizes (1–2 kb) of many contigs, only PKS fragments
encoding for merely one or two PKS domains could be identi-
fied. Overall, the contigs were not extensive enough to allow
the assembly of even parts of a biosynthetic gene cluster.
One of the contigs, however—contig 1540, with a size of
5035 bp—included a KR domain, an acyl carrier protein (ACP),
and a TE domain, and was coincident with the projected final
biochemical reactions of phenylnannolone A biosynthesis.
By screening of a fosmid library with primers deduced from
the TE domain of contig 1540 (primer pair 1540.F/1540.R,
Table S1 in the Supporting Information) the fosmid clone 12A9
was identified. This clone was then assayed by PCR (primer
pair KS1up/KSd1, Table S1, Figure S1) for the presence of se-
quences coding for KS domains. Subsequently, the fosmid
clone 12A9 was completely sequenced, thereby providing se-
quence information for 36839 bp.
Sequence analysis of the phenylnannolone A biosynthetic
genes
Sequence analysis of fosmid 12A9 revealed 12 open reading
frames (orfs) (Table 1). Two could be assigned as putatively
involved in the biosynthesis of phenylnannolone A and were
named phn1 and phn2. In a BLASTp analysis, the gene product
of phn1 showed 70% identity to the b-subunit of the putative
propionyl-CoA carboxylase (PCC) from the myxobacterium Ple-
siocystis pacifica SIR-1 (Table 1). Such proteins act as carboxyl
transferases involved in precursor supply in fatty acid or poly-
ketide biosynthesis.[12] Phn2 revealed 47% identity to a gene
encoding for a PKS of Streptomyces violaceusniger Tu 4113
(Table 1). A detailed analysis of the 22 kb gene gave evidence
for the presence of a complete PKS consisting of five modules.
The first module contains an AMP-ligase/synthetase and an
ACP domain and would therefore expected to be the loading
module. The two following modules showed the domain order
KS-AT-DH-KR-ACP. Extension module 3 (KS-AT-ACP) lacks the
reductive domains. The last extension module, extension
Scheme 1. Structures of phenylnannolones A (1), B (2), and C (3) from N. pu-
silla. Biosynthetic building blocks of phenylnannolone A (in bold). Feeding
experiments in N. pusilla B150 with 13C-labeled precursors showed incorpora-
tion of a phenylalanine-derived starter unit (C10–C17), one butyrate unit (C7,
C8, C18, C19), and three acetate units. The incorporation of an acetate C-2
at position 9 is unprecedented.
Figure 1. Phylogenetic tree of halotolerant and halophilic myxobacteria,
based on 16S rDNA sequences. Numbers indicate the corresponding boot-
strap values. The specific natural products isolated from the corresponding
clade are named on the right-hand side. The phenylnannolones (bold) are
the first compounds for which biosynthetic genes were identified. The ter-
restrial myxobacterium Myxococcus xanthus represents the outgroup. P.p. :
P. pacifica. P.s. : Pseudenhygromyxa salsuginis. Complete strain names and
accession numbers are given in Figure S20.
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module 4, showed a domain architecture comparable to that
of the extension modules 1 and 2 (KS-AT-DH-KR-ACP) plus a C-
terminal TE domain, hypothesized to be responsible for the
release and cyclization of the assembled molecule.
Domains encoded on phn2
Multiple sequence alignment of the deduced protein sequen-
ces of the KS domains showed the presence of the highly con-
served catalytic triad (C-H-H), essential for decarboxylative con-
densation (Figure S5), in all four cases.[13] Likewise, all five ACPs
were considered active domains because they harbor the con-
served serine residue (Figure S4).[14]
Each of the four extension modules of Phn2 showed the
presence of an AT domain (AT1–AT4). AT2, AT3, and AT4 clearly
displayed the conserved motifs of malonyl-CoA-specific AT do-
mains (Figure S6).[15,16] AT1 is, however, distinguished from the
other AT domains (Figure S7) because it has the highest ho-
mology (57% identity) to an AT domain of TgaA, a PKS from
Sorangium cellulosum (Figure S6). This TgaA AT domain, harbor-
ing a YASH as motif III, is located in the second module of the
thuggacin A PKS and is reported to recognize a methylmalo-
nate unit as its substrate.[17] Although malonyl- and methylma-
lonyl-CoA-specific ATs can be distinguished reasonably reliably
at the molecular level, there are fewer differences between
methylmalonyl- and ethylmalonyl-CoA-specific ATs. For methyl-
malonyl-CoA-specific ATs, three conserved motifs (RDVVQ,
GHSxG, and YASH) are described.[16] The first two motifs are
nearly identical to those present in ethylmalonyl-CoA-specific
ATs and thus not useful for discrimination; this leaves only the
slight variations in the YASH motif. Like methylmalonyl-CoA-
transferring ATs, which with a few exceptions always bear
a serine as the third amino acid in the xAxH motif (motif III),
those for ethylmalonyl-CoA also harbor small amino acids at
the corresponding site, but with broader variety: that is, gly-
cine, threonine, serine, and alanine (Figure S8). The xAxH motif
(motif III, Figures S6 and S8) in AT1 is represented as CATH,
which is a previously undescribed motif for an AT domain. The
presence of threonine as the third amino acid in this motif is
comparable to the situation in the ethylmalonyl-CoA-transfer-
ring ATs from oligomycin and ascomycin biosynthesis (Fig-
ure S8).[18, 19] The tyrosine (Y) in the YASH motif (i.e. , xAxH motif
in general) is required for the formation of a hydrophobic
pocket, important for binding the substrate. As AT1 contains
a C residue at this site, it is important to note that, in some
cases, it has been reported that this first amino acid residue of
the motif is altered, being replaced by, for example, a valine or
a tryptophan residue.[15,16] Indeed, our multiple sequence align-
ments (Figure S8) revealed that in ethylmalonyl-CoA-transfer-
ring ATs valine, cysteine, threonine, or isoleucine are observed
at this position. This is in accordance with AT1 being an ethyl-
malonyl-CoA-transferring AT.
If all available data are taken together, the xAxH motif—that
is, CATH in AT1—appears to have a preference for ethylmalon-
yl-CoA as substrate. This hypothesis is supported by our feed-
ing experiments with 1-13C-butyrate, which was incorporated
into phenylnannolone A to form the ethyl side chain of the
metabolite.[7] Furthermore, substrate preference for ethylma-
lonyl-CoA is corroborated by the production rates of the differ-
ent phenylnannolone derivatives. Observed production of the
ethyl-branched phenylnannolone A was seven times higher
than that for the methyl-branched phenylnannolone B.[7] The
occurrence of phenylnannolone B suggests that AT1 can also
activate methylmalonyl-CoA, but only to a minor extent. This
activity might result not only from a higher specificity of AT1
towards ethylmalonyl-CoA, but possibly also from a better
supply of the precursor ethylmalonyl-CoA putatively provided
by Phn1.
Table 1. Deduced functions of open reading frames of the fosmid carrying the phenylnannolone biosynthetic genes phn1 and phn2 (gray).
Gene Size Highest homology (protein level) Putative function Identity of aligned GenBank
[kb] amino acids[a] accession no.
orf1 1.7 hypothetical protein MYSTI_00784 ANK superfamily, SMI1-KNR4 family protein 67/184 YP_007357817.1
[Myxococcus stipitatus DSM 14675] (36%)
orf2 0.9 hypothetical protein ANK superfamily protein 86/241 WP_019929995.1
[Nocardia sp. BMG111209] (36%)
orf3 0.5 hypothetical protein SCE1572_14840 SMI1-KNR4 family protein 87/126 YP_008149402.1
[Sorangium cellulosum So0157-2] (69%)
orf4 0.7 hypothetical protein unknown 43/103 WP_006974326.1
[Plesiocystis pacifica] (42%)
orf5 0.9 RNA polymerase RNA polymerase 70/161 YP_008148278.1
[Sorangium cellulosum So0157-2] (43%)
orf6 0.8 leucine-rich repeat protein unknown 71/267 WP_004424624.1
[Leptospira noguchii] (27%)
phn1 1.7 propionyl-CoA carboxylase, b-subunit carboxyl transferase subunit 373/535 EDM78666.1
[Plesiocystis pacifica SIR-1] (70%)
phn2 22 b-ketoacyl synthase PKS 2174/4630 YP_004817600.1
[Streptomyces violaceusniger Tu 4113] (47%)
orf7 0.4 hypothetical protein unknown 28/97 WP_021290293.1
[Virgibacillus sp. CM-4] (29%)
[a] Ratio of identical amino acids (first value) to all compared amino acids (second value).
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Sequence analysis of the three ketoreductase (KR) domains
in Phn2 revealed the presence of the Rossmann fold motif
GxGxxG and the K-S-Y catalytic triad, required for activity (Fig-
ures S9 and S10). The highly conserved active site motif
Dxxx(Q/H), responsible for catalyzing the elimination of the b-
hydroxy group to generate an a,b-unsaturated moiety, was
identified for all dehydratase (DH) domains of Phn2 (Fig-
ure S11). For the motif LxxHxxxGxxxxP, however, mutations of
the conserved leucine (in the DH2 domain) and glycine (in DH1
and DH2) were observed (Figure S11).
[20]
The KR domains of the phenylnannolone A biosynthetic
genes were characterized by analyzing several conserved
motifs that allowed stereochemical prediction.[21,22] KR1 and KR2
were identified as B1-type KR domains, resulting in a d-
hydroxy-substituted thioester and, through the action of the
neighboring DH domain, finally in a trans double bond. KR4,
however, lacks the LDD motif (motif II) present in KR1 and KR2
that is found in “B-type” KRs, but also lacks the conserved tryp-
tophan residue (motif III) present in “A-type” KRs (Figure S9).
Although tryptophan is present in nearly all A-type KRs, there
are a few examples of KR domains that generate l-hydroxy
groups despite a missing tryptophan motif (i.e. , the corre-
sponding domains in stigmatellin, chivosazol, and disorazole
biosynthesis).[23–25] Furthermore, KR4 from Phn2 showed (in a
BLAST analysis) the highest identity to a KR from StiD, involved
in stigmatellin biosynthesis in Stigmatella aurantiaca. This KR
from StiD converts the b-keto group to an l-hydroxy group,
which in this case is subsequently methylated through the
action of a methyltransferase (Figures S9 and S17).[23] Our con-
clusions are additionally supported by the fact that in chivosa-
zol biosynthesis KR4 and KR14 are classified as A-type KRs,
which catalyze the formation of cis double bonds. Both KRs
lack the conserved tryptophan residue, which is replaced by
leucine and valine, respectively.[24] A third example of a set of
A-type KRs lacking the tryptophan motif is found in the disora-
zole (Figure S17) gene cluster, in which the tryptophan resi-
dues in KR4, KR5, and KR7 are replaced by valine, methionine,
and leucine, respectively.[25] If we take note of all these exam-
ples of A-type KRs without the typical tryptophan motif, it is
very likely that KR4 in Phn2 generates an l-hydroxy group, and
that this is further processed by DH4 to afford a cis double
bond. For the biosynthesis of phenylnannolone A a cis configu-
ration in this position is necessary to facilitate the formation of
the lactone ring.
The TE domain located at the C terminus of Phn2 included
the conserved motif GxSxG and the active site triad S-D-H (Fig-
ure S12).[26] For the formation of the terminal pyrone ring of
phenylnannolone A, keto–enol tautomerism of the unreduced
carbonyl group (module 3), resulting in an enol functionality,
would be expected (Figure S18). TE-induced pyrone ring for-
mation is uncommon for modular type I PKSs. Triketide lactoni-
zation has previously been studied in the case of DEBS 1-TE,
a truncated form of the erythromycin polyketide synthase.[27,28]
A further example of pyrone formation in a type I PKS, follow-
ing a mechanism similar to that proposed for phenylnannolo-
ne A, is represented in jerangolid biosynthesis.[29]
Phn1 and precursor supply with ethylmalonyl-CoA
PKS extender units such as methoxymalonyl-CoA, hydroxyma-
lonyl-CoA, and ethylmalonyl-CoA are less common in poly-
ketide biosynthesis, and their supply is a limiting factor in such
biosynthetic processes.[30]
Ethylmalonyl-CoA can be produced from crotonyl-CoA
through the action of the enzyme crotonyl-CoA carboxylase/
reductase (CCR), belonging to the ethylmalonyl-CoA path-
way.[31,32] Because only a few bacteria have an operating ethyl-
malonyl-CoA pathway (apart from secondary metabolic path-
ways), most biosynthetic gene clusters for ethyl-substituted
polyketides harbor a gene encoding a CCR homologue: such
as, concanamycin, oligomycin, or tylosin.[18,33,34]
Other proposed pathways for the formation of ethylmalonyl-
CoA require the carboxylation of butyryl-CoA. Butyryl-CoA
might be derived either from l-valine, which is catabolized to
isobutyryl-CoA and then converted into butyryl-CoA, or from
b-oxidation of even-chain fatty acids.[35,36] In each case acyl-
CoA carboxylases are responsible for the carboxylation reaction
(Figure S16).
The biosynthetic gene clusters of indanomycin and tiacumi-
cin were found to harbor both types of enzymes: that is, the
CCR and the acyl-CoA carboxylase. In the case of indanomycin
the involvement of an acyl-CoA carboxylase (IdmB) responsible
for the supply of both ethylmalonyl-CoA and methylmalonyl-
CoA was discussed. This enzyme harbors an isoleucine at posi-
tion 422, the active site residue. It was thus postulated that
IdmB accepted substrates such as acetyl-CoA, propionyl-CoA,
and butyryl-CoA with almost equal affinities, just like acetyl-
CoA carboxylases.[37,38] For the precursor supply in tiacumicin B
biosynthesis, three genes encoding for enzymes of the ethyl-
malonyl-CoA pathway—a hydroxybutyryl-CoA dehydrogenase
(TiaJ), a crotonyl-CoA hydratase (TiaN), and a crotonyl-CoA car-
boxylase (TiaK)—were identified. In addition to these three
enzymes that form ethylmalonyl-CoA, another enzyme, a PCC
encoded by tiaL, is believed to supply the PKS with methylma-
lonyl-CoA.[39] Multiple sequence alignment with sequences of
different PCCs revealed the active site residue for TiaL to be an
isoleucine (Figure S2). It was thus suggested that the affinity of
this PCC was comparable with that of IdmB. This conclusion is
supported by crystal structure and mutational analysis of the
b-subunit of a PCC from Streptomyces coelicolor.[37,40]
With regard to the biosynthesis of phenylnannolone A, the
supply of ethylmalonyl-CoA putatively results from the enzy-
matic reaction of Phn1, a proposed b-subunit of a carboxylase
(Table S2). This b-subunit acts as a carboxyl transferase, where-
as the a-subunit harbors the biotin-carboxylase (BC) and
biotin-carboxylase-carrier protein (BCCP) domain.[37,41] IdmB
from Streptomyces antibioticus also displays only the b-subunit
of an acyl-CoA carboxylase. Li et al. discussed the formation of
an active complex with partnering BC and BCCP, encoded else-
where within the genome of the strain in question.[38]
The active site residue of Phn1 is an alanine unit, rather than
the conserved aspartate residue found in PCCs (Figure S2). Mu-
tational experiments for a PCC in S. coelicolor showed that mu-
tations of this type led to a clear shift in substrate preference
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from propionyl-CoA to butyryl-CoA.[37,40] Phn1 is thus more
likely a butyryl-CoA carboxylase (BCC) than a PCC, and hence
preferentially provides ethylmalonyl-CoA for the PKS assembly
line. This is also corroborated by the ratio of amounts of
phenylnannolone A (2.8 mgL1) and phenylnannolone B
(0.4 mgL1) produced in vivo, showing a sevenfold higher
prevalence for ethylmalonyl-CoA over methylmalonyl-CoA.[7]
Phn1 is to the best of our knowledge the first putative BCC
found in a biosynthetic gene cluster for an ethyl-substituted
natural compound.
Biochemical characterization of the AMP-ACP didomain
The functionality of the biosynthetic genes was tested by bio-
chemical characterization of distinct enzymes because N. pusil-
la B150 is not yet genetically accessible and thus no standard
protocols for mutagenesis are available for this species. A puta-
tive loading module forms the N-terminal part of Phn2, it con-
sists of a didomain: that is, an AMP-ligase (Figure S3, Table S2)
and an ACP. To investigate the substrate selectivity of the puta-
tive AMP-ligase, heterologous expression of the recombinant
apo-AMP-ACP didomain was projected with the goal of per-
forming ATP-PPi exchange assays. The assay, described by
Phelan et al. , measures the isotopic back exchange of unla-
beled pyrophosphate into g-18O4-labeled ATP.
[42] To obtain the
80 kDa apo-AMP-ACP didomain, pet151AMPACP was expressed
in E. coli BL21, and expression was confirmed by SDS-PAGE
(Figures S13 and S14). We expected from the isotope labeling
studies that either a C6C2 or a C6C3 moiety forms the starter
unit, and so phenylacetic acid (C6C2) and several phenylpropa-
noids (C6C3) were tested in the ATP-PPi exchange assay. For the
apo-AMP-ACP didomain, selectivity towards cinnamic acid was
observed, with an ATP-PPi exchange of 47% being measured
for this C6C3 unit (Figure 2). Hydrocinnamic acid showed only
a third of this exchange activity (17.7%). All other applied sub-
strates—phenylacetic acid, d-/l-phenylalanine, phenyllactic
acid, and phenylpyruvic acid—did not reach more than 1.1%
exchange activity (Figure S19, Table S4). Characterization of the
loading didomain (A-PCP) from McyG (Table S3), an NRPS/PKS
system involved in microcystin biosynthesis, was reported to
show divergent results when the ATP-PPi exchange assay with
apoenzyme or alternatively a mass spectrometric analysis with
holoenzyme was employed.[43] To confirm the results of our
ATP-PPi exchange assay and to characterize the substrate
loaded onto the phosphopantetheine (PPant) arm of the load-
ing didomain (AMP-ACP) directly, loading studies were per-
formed on the holoenzyme. The phosphopantetheinylated
holo-AMP-ACP was obtained by expression of pet151AMPACP
in E. coli Bap-1 cells. This protein was used in a PPant ejection
assay with different substrates.[44] In addition to phenylacetic
acid (C6C2), several phenylpropanoids (C6C3), such as cinnamic
acid, hydrocinnamic acid, p-coumaric acid, d-/l-phenylalanine,
phenyllactic acid, and phenylpyruvic acid, were tested. Mass
spectrometric analysis showed that the loading of three sub-
strates was successful : that is, cinnamic acid, p-coumaric acid,
and phenyllactic acid (Scheme 2). On provision of a mixture of
cinnamic acid and phenyllactic acid to the holoenzyme, only
cinnamic acid was loaded to the PPant arm of the AMP-ACP di-
domain.
From the results of these assays we can conclude that, for
the formation of phenylnannolone A, cinnamic acid is adeny-
lated by the AMP-ligase and subsequently loaded to the neigh-
boring ACP domain. The activation and loading of p-coumaric
acid by the holo-AMP-ACP didomain explains the formation of
phenylnannolone C, which possesses an additional hydroxy
group on the phenyl moiety and is only produced in trace
amounts by N. pusilla B150.
With regard to our previous feeding experiments, which
suggested the incorporation of a phenylacetic acid unit rather
than cinnamic acid, there are still some open questions to be
answered. In this context, it is useful to refer to similar experi-
ments with the cyanobacterium Microcystis aeruginosa, in
which phenylalanine was incorporated into microcystin in the
same manner.[43] The same applies to the starter units in the
biosynthesis of nodularin and cryptophycin, both isolated from
cyanobacteria.[45–47] Biochemical characterization of the A-PCP
didomain from McyG, an NRPS/PKS system involved in micro-
cystin biosynthesis, revealed that several phenylpropanoids
(C6C3) are preferentially activated and loaded onto the PCP
domain, rather than the postulated phenylacetic acid (C6C2).
Indeed, in vivo loading experiments pointed towards 3-phenyl-
lactate, now considered to be the true starter unit of microcys-
tin.[43] However, a remaining mystery is the mechanistic basis
for the one-carbon truncations from C6C3 to C6C2 units in the
biosyntheses of microcystin, cryptophycin, nodularin, and, in
our case, phenylnannolone.[43,47]
The biosynthesis of cinnamic acid in a few bacteria—that is,
Streptomyces maritimus, Photorhabdus luminescens, Legionella
spp., and two strains of cyanobacteria (Anabaena variabilis and
Nostoc punctiforme)—is mediated by a phenylalanine ammonia
lyase (PAL).[48–51] In a single reaction, PAL transforms phenylala-
nine into trans-cinnamic acid, with every carbon atom being
preserved and no carbon cleavage taking place. However, this
Figure 2. Relative activities of the AMP domain from Phn2, measured in an
g-18O4-ATP pyrophosphate exchange assay.
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does not explain the unusual results of our feeding experi-
ments, in which a single carbon atom, derived from acetate, is
incorporated. The formation of the starter unit (that is, cinnam-
ic acid) in N. pusilla B150 remains elusive and probably in-
cludes a new pathway, a suggestion for which is presented in
Figure S15. Cinnamoyl-CoA is quite a common starter molecule
in type III PKSs of plants and bacteria, as observed for stilbene,
curcumin, and flavonoid biosynthesis.[52,53] For the modular
type I PKSs however, cinnamoyl-CoA is an uncommon starter
unit, although recently reported to be involved in the PKS as-
sembly line of legioliulin.[51]
Model for phenylnannolone A biosynthesis
The putative biosynthetic genes for phenylnannolone A consist
of a putative carboxyl transferase gene (phn1) and a modular
type I PKS gene (phn2).
It is proposed that the carboxyl transferase, encoded by
phn1, is responsible for the supply of the ethylmalonyl-CoA
precursor. The adjacent PKS enzyme consists of five modules:
a loading module and four extension modules. From the
domain order of the PKS encoded by phn2 a colinear biosyn-
thetic pathway for the formation of phenylnannolone A can be
proposed (Scheme 3). The loading module, comprising an
AMP-dependent ligase/synthetase (AMP), thus adenylates the
putative starter cinnamic acid and hence enables its loading to
the adjacent acyl carrier protein (ACPLM) domain. This was
shown experimentally in an ATP-PPi exchange assay and
through MS-based ACP loading studies. In the following step,
KS1 of the first extension module prolongs the starter unit with
a butyrate moiety, loaded by AT1, in a decarboxylative Claisen
condensation, and this is followed by reduction and dehydra-
tion, through the action of the corresponding KR1 and DH1 do-
mains, to form a trans-configured C=C double bond. In the
second elongation step (module 2), the growing chain is ex-
tended with an acetate unit, and this is then reduced and de-
hydrated in the same manner as in the step before. The third
elongation module is also responsible for the extension of the
polyketide chain with an acetate unit, with the difference that
the b-keto group is not further reduced. This feature is appar-
ent from the domain order, because no reductive domains are
present in this module. The extender unit of the last step is
again malonyl-CoA, which elongates the polyketide chain with
a final acetate unit. The corresponding KR reduces the b-keto
group to an l-hydroxy group, and this is then eliminated
through the action of DH4 to form a cis double bond. The ste-
reochemistry generated in this way is necessary for the lactone
ring formation and thereby for the release of the polyketide
from the assembly line through the thioesterase domain.
Conclusions
We have presented the first biosynthetic pathway for a natural
compound from the genus Nannocystis. For the biosynthesis of
the structurally novel and bioactive phenylnannolones, we
conclude that phenylnannolone A is the product of an unusual
PKS system in N. pusilla B150. Bioinformatic analysis of phn1
and phn2 showed that the domain order of the identified
genes is consistent with the chemical structure of phenylnan-
nolone A and also explains the occurrence of minor metabo-
lites. In addition, biochemical studies on the loading module of
the putative phenylnannolone gene product Phn2 were per-
formed, and indicate cinnamic acid to be the starter unit. To
the best of our knowledge this represents the first example of
a BCC/PKS system in microbial biosynthesis.
Scheme 2. Pantetheine (Pant) ejection assay on the holo-AMP-ACP loading didomain. Acylation of the holo-AMP-ACP didomain was observed for three sub-
strates: cinnamic acid, p-coumaric acid, and phenyllactic acid, with ejection ions of m/z 391.1664, m/z 407.1645, and m/z 409.5884 being measured by FTMS.
Correspondingly, MS3 resulted in signature ions of the Pant arm with the mass of m/z 261.1277. MS4 of the substrate fragment yielded another series of corre-
sponding signature ions (m/z 243.2 to 142.1; see Meluzzi et al. , 2008)[44] verifying the presence of the PPant arm. Substrates such as phenylacetic acid, phenyl-
pyruvic acid, l-phenylalanine, d-phenylalanine, and hydrocinnamic acid were not loaded.
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Experimental Section
Biological material : The myxobacterial strain B150 was isolated by
Birgit Ohlendorf from a soil sample collected from the intertidal
region of Crete, Greece. The 16S rDNA sequence of the myxobacte-
rial strain was closely related to that of N. pusilla strain DSM
14622T (GenBank accession: FR749907.1) with an identity between
the two sequences of 98%. This outcome supports the previous
classification of this strain to the genus of Nannocystis.[7] Whereas
Ohlendorf et al. , however, suggested the species to be Nannocystis
exedens, our result points towards N. pusilla B150. For bacterial
growth, a cryo-culture (250 mL) of N. pusilla B150 was placed on
VY/2 agar plates. For cultivation in liquid medium, slices of agar,
containing fruiting bodies of the myxobacterium, were inoculated
in MD-1 glucose medium and grown at 30 8C for seven days under
shaking conditions (140 rpm). For long-term storage at 80 8C, the
liquid bacterial cultures were mixed with an equal volume of casi-
tone (1%).
General procedure : N. pusilla strain B150 (Figure S23 for 16S
rDNA) was grown in liquid MD1+glucose medium at 30 8C
(140 rpm) for seven days. E. coli XL1Blue was used as a host for
routine cloning and construction of targeting plasmids. E. coli
strains were grown in lysogeny broth (LB) supplemented with am-
picillin at a final concentration of 100 mgmL1. All restriction en-
zymes and T4 DNA ligase were purchased from MBI Fermentas.
DNA polymerases and dNTPs for PCR were obtained from Prome-
ga. Oligonucleotides were purchased from MWG-Biotech AG
(Ebersberg, Germany). Gel electrophoresis materials were supplied
from Neolab (Heidelberg, Germany). All other materials and sub-
stances were supplied by Roth. Isolation of plasmid DNA and chro-
mosomal DNA, as well as E. coli strain transformation, were per-
formed by standard methods.[54] DNA fragments were isolated
from agarose gels with a QIAquick Gel Extraction Kit (Qiagen). For
preparation of DNA templates for sequencing, the pGEMT vector
(Promega) was used. Plasmid DNA purification was performed with
a GeneJET Plasmid Miniprep Kit (Fermentas) or the PureYield Mini-
prep System (Promega). PCR was carried out with Taq DNA poly-
merase or Pfu-DNA polymerase (Promega). DMSO was added to
the reaction mixture to a final concentration of 5%. Conditions for
amplification with use of a Thermoycler TGradient (Biometra, Gçt-
tingen, Germany) were as follows: initial denaturation for 120 s at
95 8C, annealing for 30–45 s at 45–60 8C, extension for 60–90 s at
72 8C, denaturation for 30 s at 95 8C, 30 cycles, and a final extension
for 5 min at 72 8C. PCR products were purified with a QIAquick PCR
Purification Kit (Qiagen).
Construction of the fosmid library : Chromosomal DNA derived
from a 500 mL culture of N. pusilla B150 was used for the construc-
tion of a fosmid library with use of pCC1FOS (Epicentre, Madison,
USA). The genomic library was constructed according to manufac-
turer’s instructions, and 2300 colonies with an average insert
length of 36 kb were generated and transferred to 95-well microtit-
er plates. For long-term storage at 80 8C the fosmid cultures were
mixed with an equal volume of glycerol (100%).
Screening of the fosmid library : The fosmid gene library was
screened by whole-cell PCR for the presence of PKS-TE domain
positive clones with use of the specific primer pair 1540.F/1540.R
deduced from sequence data of contig 1540 (obtained from 454
genome sequencing steps). In order to make the fosmid DNA ac-
cessible for the Taq-polymerase, a heating step was integrated into
the previously described standard PCR program. This denaturation
step at the beginning of the PCR procedure was performed at
95 8C for 20 min to initiate cell lysis (whole-cell PCR). To facilitate
fast screening of the library, all 96 clones of each microtiter plate
were combined in 0.5 mL Eppendorf tubes. Whole-cell PCRs were
set and performed with 1 mL of each pool. PCR probes were subse-
quently analyzed by agarose gel electrophoresis for a fragment of
800 bp. Positive clones were then analyzed in a second PCR with
the deduced KS primer pair for existing ketosynthase domains,
necessary for the PKS assembly line. Degenerate PKS primers were
deduced from conserved sequence motifs of KS domains, obtained
from 454 genome sequencing steps, yielding fragments of 700 bp
in the PCR.
Scheme 3. Proposed pathway for the biosynthesis of phenylnannolone A. BCC: butyryl-CoA carboxylase. AMP: AMP-dependent ligase. ACP: acyl carrier pro-
tein. KS: ketosynthase domain. AT: acyltransferase domain. DH: dehydratase domain. KR: ketoreductase domain. TE: thioesterase domain.
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Sequencing of genomic DNA and fosmid clone of N. pusilla
B150 : Genome sequencing was carried out by GATC Biotech AG
(Konstanz, Germany) with a Roche Genome Sequencer FLX Titani-
um (F. Hoffmann–La Roche). Raw sequences were assembled by
the company; this resulted in a draft genome with 3804 contigs of
an average contig size of 3 kb. Complete sequencing of fosmid
12A9 was performed by IIT-BiotechGmbH (Bielefeld, Germany). For
this purpose a high-throughput library with an insert length of
500 bp was constructed and subsequently analyzed in a pyrose-
quencing reaction with a Roche GS FLX Titanium+ instrument.
Samples were sequenced with a Roche 454 GS FLX Titanium Se-
quencer (Roche). The sequence of the phenylnannolone genes
were deposited in Genbank with accession number KF739396.
Bioinformatic analysis of sequences : The software programs
Clone Manager 9, CLUSEAN, and Artemis were used to attend DNA
sequences. The BLAST program provided by NCBI was used for se-
quence data analysis. The multiple alignments of nucleotide se-
quences were generated with the program ClustalW powered by
EMBL. For the construction of the phylogenetic tree in Figure 1, se-
quences were aligned by usingthe heuristic Smith–Waterman algo-
rithm with mafft. Subsequently, the multiple sequence alignment
was filtered with Gblocks for conserved regions. The phylogenetic
tree was constructed by use of FastTree. FastTree computes local
support values with the Shimodaira–Hasegawa test (bootstrap
values). For the construction of the phylogenetic trees in the Sup-
porting Information the online tool provided by Phylogeny.fr was
used.[55,56]
Expression and purification of the loading didomain : The DNA
sequence of the loading didomain was amplified from the DNA of
the fosmid clone 12A9 by PCR by using the primer pair revAM-
PACP/forAMPACP (Eurofins MWG Operon) and a pfu-Polymerase
(Promega). The resulting PCR fragment (AMP-ACP) of 2.26 kb en-
coding for the two domains was cloned into the pet151/D-TOPO
cloning vector (Invitrogen) and transferred into One Shot TOP10
Chemically Competent E. coli cells (Invitrogen). To exclude the pos-
sibility of mutations in the reading frame, the chosen clones were
submitted for sequencing. Plasmid DNA (pet151AMPACP) was iso-
lated from confirmed clones and transformed into BL21 Star(DE3)
One Shot Chemically Competent E. coli cells (Invitrogen). For a pre-
culture, LB (10 mL) with ampicillin (100 mLmL1) was inoculated
with transformed cells (500 mL), and these were grown overnight
at 37 8C. For the main culture, LB (100 mL) containing ampicillin
(100 mLmL1) was inoculated with the overnight culture (2 mL).
After inoculation, the main culture was grown to an OD600 value of
0.5. Protein expression was induced by adding isopropyl b-d-1-
thiogalactopyranoside (IPTG) to a final concentration of 0.5 mm.
The expression of the recombinant protein took place at 37 8C and
was stopped after 4 h. Cells were harvested and resuspended in
lysis buffer [NaH2PO4 (50 mm), NaCl (300 mm), imidazole (10 mm),
pH 8.0] . Cells were lysed with the help of a Branson Sonifier 250,
set to output level 4, 50% duty cycle. The samples were sonified
four to five times with ten pulses each. Between the pulses the
cells were placed back on ice to avoid overheating of the sample.
Cell debris and insoluble parts were pelleted by centrifugation for
10 min at 10016g and 4 8C. The supernatant containing the soluble
proteins and the pellet were collected. The supernatant containing
the His-tagged protein was bound to Ni-NTA spin columns
(Qiagen), and the pure AMP-ACP didomain was eluted with elution
buffer [NaH2PO4 (50 mm), NaCl (300 mm), imidazole (150 mm),
pH 8.0] , according to the manufacturer’s instructions. Protein was
used directly in assays. For the expression of the holo-AMP-ACP,
pet151AMPACP was transferred into chemically competent BAP-
1 E. coli cells. The cells were cultured and purified under the same
conditions as the apo-AMP-ACP protein. All proteins were analyzed
by separation through a 12% SDS-PAGE gel [Tris·HCl (pH 6.8, 1m,
2.5 mL), SDS (10%, 0.1 mL), bis-acrylamide (30%, 4 mL), H2O
(3.3 mL), APS (10%, 0.1 mL), TEMED (4 mL)] and visualized by Coo-
massie Blue staining.
Adenylation enzyme characterization by g-18O4-ATP pyrophos-
phate exchange : In this assay the isotopic back exchange of unla-
beled pyrophosphate into g-18O4-labeled ATP was measured.
[42] Re-
actions were each performed in a total volume of 6 mL [MgCl2
(5 mm), PPi (5 mm), g-
18O4-ATP (1 mm, or
16O4-ATP as a positive con-
trol), Tris·HCl (pH 7.5, 20 mm), and substrate (1 mm)] . The reactions
were carried out for 2 h at room temperature after addition of the
purified A domain, and were then stopped by the addition of the
same volume of 9-aminoacridine in acetone (10 mgmL1). As a neg-
ative control, instead of enzyme, buffer was added to the reaction
mixture. Samples were then analyzed by MALDI-TOF MS.
Adenylation enzyme characterization by mass-based PPant ejec-
tion assay : A typical sample (50 mL total volume) consisted of ATP
(3 mm), A domain buffer [Tris·HCl (pH 7.5, 20 mm), glycerol (5%)],
substrate (10 mm), and holo-AMP-ACP (15 mL), and was incubated
for 30 min at room temperature. The assay mixture was placed
on ice, before being subjected to semipreparative RP-HPLC (C4
reversed-phase column, Symmetry 300, 5 mm, 4.6 mm250 mm,
Waters, eluent water/acetonitrile (70:30) to water/acetonitrile
(35:65) over 35 min, flow rate 1.0 mLmin1). The retention time of
the protein loaded with substrate was 29 min. The protein-contain-
ing fraction was collected manually and dried in a SpeedVac con-
centrator.
MSn analysis : The lyophilized samples were dissolved in a suitable
volume of electro spray solution [H2O (49.5%), methanol (49.5%),
formic acid (1%)]. Use of a Thermo LTQ Orbitrap Velo coupled with
an Advion TriVersaNanoMate enabled a continuous electron spray
for the MSn experiments. Samples (20–50 mL) were loaded onto
the 96-well plate of the NanoMate spray robot coupled to the LTQ
Orbitrap Velos. A spray chip (5 mm nozzle diameter) was used at
a spray voltage of 1.6 kV and 0.3 psi pressure setting. An environ-
mental polysiloxane ion with m/z 445.12003 was used as lock mass
for internal calibration. Isolation and fragmentation were per-
formed in the linear ion trap, and detection of the final product
spectrum was achieved with the Orbitrap analyzer. For holo-AMP-
ACP with a mass of 80 kDa the ejection ions were obtained by in-
source fragmentation, with application of 50–65 V fragmentation
energy. The resulting ejection ions were isolated and subjected to
a further round of fragmentation (MS3) to liberate the PPant arm
(calculated m/z 261.1267). To verify that these ions (measured m/z
261.1277) really represent the PPant arm, they were subjected to
an additional round of fragmentation (MS4), and the ions obtained
were analyzed for the typical PPant signature.[20]
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